| Sinovac Wins Order for China’s National Immunization Program ChinaBio Today submits: Sinovac Biotech (NSDQ: SVA) was selected to supply its hepatitis A vaccine, Healive®, to the Beijing Expanded Program of Immunization [EPI]. Sinovac was selected one of the two suppliers and was allocated a greater share of the total purchase order. The decision was made by the Beijing CDC, which evaluated suppliers on the basis of several criteria, including product quality, service and price. The order was for 477,000 doses. As a point of reference, Healive orders for the third quarter of 2009 were almost 1 million.Complete Story » seekingalpha.com |
Obama Warns Insurers on Rates Obama told health-insurance executives they should keep a lid on big rate increases, but the executives said some rises were unavoidable because the new health law requires them to offer better benefits. online.wsj.com |
Sigma Agrees to Sell Drug Unit to Aspen Sigma Pharmaceuticals will sell its pharmaceutical division to South Africa's Aspen Pharmacare for $803.5 million. online.wsj.com |
Idenix Hopes to Resume Course With Hepatitis C Drugs by Year's End The Burrill Report submits: By Michael FitzhughIdenix Pharmaceuticals (IDIX) halted a mid-stage study of two hepatitis C drugs after the U.S. Food and Drug Administration ordered it to suspend the trial over safety concerns. The news led investors to sink the company's shares on worries about the program's future. Complete Story » seekingalpha.com |
FDA Extends Review of Merck Drug The U.S. Food and Drug Administration extended its review of German drug maker Merck's potential blockbuster Cladribine, feeding hope the treatment could be approved despite a negative opinion from European authorities. online.wsj.com |